Announced
Completed
Financials
Tags
treatment of fungal infections
Pharmaceuticals
cream products
Cross Border
Acquisition
Private
Majority
Single Bidder
Friendly
Completed
United Kingdom
Synopsis
Karo Healthcare, a European consumer healthcare company, completed the acquisition of Lamisil, a brand for the treatment of fungal infections like Athlete’s foot, from Haleon, a consumer healthcare company, for £235m. “We are pleased to add the global well-known and trusted brand, Lamisil, to our portfolio,” Christoffer Lorenzen, Karo CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.